XML 47 R35.htm IDEA: XBRL DOCUMENT
v3.23.1

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended
--- | ---
Mar. 31, 2023 | Mar. 31, 2022
Disaggregation of Revenue [Line Items] |  |
Total revenues | $ 12,982 | $ 35,340
Americas |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 2,584 | 3,732
EMEA |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 3,089 | 4,127
APAC |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 7,309 | 27,481
Product revenue |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 8,364 | 30,690
Research and development revenue |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 4,618 | 4,650
Performance Enzymes |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 9,486 | 33,099
Performance Enzymes | Americas |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 918 | 2,553
Performance Enzymes | EMEA |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,259 | 3,065
Performance Enzymes | APAC |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 7,309 | 27,481
Performance Enzymes | Product revenue |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 8,364 | 30,690
Performance Enzymes | Research and development revenue |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,122 | 2,409
Novel Biotherapeutics |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 3,496 | 2,241
Novel Biotherapeutics | Americas |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,666 | 1,179
Novel Biotherapeutics | EMEA |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,830 | 1,062
Novel Biotherapeutics | APAC |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 0 | 0
Novel Biotherapeutics | Product revenue |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 0 | 0
Novel Biotherapeutics | Research and development revenue |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | $ 3,496 | $ 2,241

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AmericasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_EMEAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=cdxs_APACMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdxs_ProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdxs_ResearchandDevelopmentRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cdxs_PerformanceEnzymesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=cdxs_NovelBiotherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |